Given Mymd Pharmaceuticals’ peers stronger consensus rating and higher possible upside, analysts clearly believe Mymd Pharmaceuticals has less favorable growth aspects than its peers. Gross Revenue Net Income Price/Earnings Ratio Mymd Pharmaceuticals N/A -$11.63 million -0.14 Mymd Pharmaceuticals Competitors $23.51 billion $3.24 billion 13.37Mymd Pharmaceuticals’ peers have higher revenue and earnings than Mymd Pharmaceuticals. Net Margins Return on Equity Return on Assets Mymd Pharmaceuticals N/A -76.40% -35.10% Mymd Pharmaceuticals Competitors -639.13% -14.37% 2.86%Risk & VolatilityMymd Pharmaceuticals has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500. SummaryMymd Pharmaceuticals peers beat Mymd Pharmaceuticals on 11 of the 13 factors compared. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024.